Dr. Keith W. Pratz, MD

Dr. Pratz practices at Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania, part of University of Pennsylvania.

Dr. Pratz's NPI, 1710966114, was assigned on January 13, 2006. Dr. Pratz holds Pennsylvania license MD467231.

Dr. Pratz's primary practice is Hospital of the University of Pennsylvania, at 3400 Spruce St, Philadelphia, PA 19104 in Philadelphia County. The practice phone is (215) 662-6289.

Dr. Pratz's primary practice is Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania, part of University of Pennsylvania. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Dr. Pratz to 2 more group practices and clinics, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pratz practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Pratz's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Pratz's licenses on file in 2 states: Pennsylvania and Maryland.

CMS data shows 845 Medicare services from Dr. Pratz across 8 procedure codes in 2024, for 150 Medicare patients. Medicare paid $56,743 for them.

CMS counts 150 Medicare patients who saw Dr. Pratz in 2024. The largest group is 65 to 74, with 73 patients. 75% of them have high blood pressure, and 69% have high cholesterol. 7% are also on Medicaid. Their average risk score is 3.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Pratz's median patient age at 69, with 41% women.

In 2024, Dr. Pratz wrote 842 Medicare Part D claims for 94 patients. 61% of them were for generic drugs. CMS names the drug for 633 of them, across 19 drugs with 11 or more claims each, at $5,066,597 in total drug cost. In 2023, CMS named 590 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Pratz for performance year 2024, reported as part of a group. Dr. Pratz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Pratz as offering telehealth.

Dmand AI links 88 papers to Dr. Pratz, published from 2011 to 2025. 2022 was the busiest year, with 12. The most frequent topics are Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols and Bridged Bicyclo Compounds, Heterocyclic. Dr. Pratz has published most often in Am J Hematol. Dr. Pratz's most frequent co-authors are Judith Karp, MD, Courtney Denton Dinardo, MD and Ivana Gojo, MD.

Dmand AI links Dr. Pratz to 7 clinical trials, 2 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Burkitt Lymphoma, Epstein-Barr Virus Infections and Leukemia, Megakaryoblastic, Acute. National Cancer Institute (NCI) sponsors the most, 4. Open Payments lists research payments to Dr. Pratz that name 2 trials.

CMS Open Payments shows 201 general payments to Dr. Pratz from 17 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 80% of the total. Abbvie Inc. paid the most, $106,997. It also lists 18 research payments totaling $7,206 from 2016 to 2023, naming 2 clinical trials.